Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Breast Cancer UpdateShow Notes
Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer. CME information and select publications here.
More from Breast Cancer Update
Featuring an interview with Dr Erica Mayer, including the following topics: Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00) Investigator Survey Results on Risk Assessment and Genomic Assays (20:07) Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30) Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42) Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07) Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44) Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05) Investigator Survey Results on Adjuvant Oral SERDs (43:02) Discussion of Questions from the Community (45:00)
Featuring perspectives from Dr Sara M Tolaney, including the following topics: Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00) Managing brain metastases in triple-negative breast cancer (6:30) EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11) PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)
Featuring perspectives from Dr Sara M Tolaney, including the following topics: Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00) First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13) First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02) Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)
Featuring perspectives from Dr David W Cescon, including the following topics: Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00) CNS activity of TROP2-directed antibody-drug conjugates (5:36) Autoimmune considerations with immunotherapy (10:09) Treatment of oligoprogressive advanced breast cancer (17:31)
Featuring perspectives from Dr David W Cescon, including the following topics: First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00) First-line treatment of mTNBC in patients eligible for immunotherapy (12:05) Adverse events (19:39)